MwanzoWXIBF • OTCMKTS
add
WuXi Biologics (Cayman) Inc
Bei iliyotangulia
$ 2.74
Bei za mwaka
$ 1.30 - $ 3.70
Thamani ya kampuni katika soko
93.97B HKD
Wastani wa hisa zilizouzwa
elfu 1.49
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
HKG
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CNY) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 5.05B | 18.25% |
Matumizi ya uendeshaji wa biashara | 767.53M | -6.22% |
Mapato halisi | 928.50M | 63.89% |
Kiwango cha faida halisi | 18.38 | 38.61% |
Mapato kwa kila hisa | — | — |
EBITDA | 1.63B | 53.35% |
Asilimia ya kodi ya mapato | 23.39% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CNY) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 10.71B | -4.75% |
Jumla ya mali | 56.98B | 0.71% |
Jumla ya dhima | 11.50B | -8.42% |
Jumla ya hisa | 45.48B | — |
hisa zilizosalia | 4.11B | — |
Uwiano wa bei na thamani | 0.27 | — |
Faida inayotokana na mali | 6.07% | — |
Faida inayotokana mtaji | 6.86% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CNY) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 928.50M | 63.89% |
Pesa kutokana na shughuli | — | — |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | — | — |
Mtiririko huru wa pesa | — | — |
Kuhusu
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2010
Tovuti
Wafanyakazi
12,575
